Moody National Bank Trust Division continued to hold its position in shares of Celgene Corporation (NASDAQ:CELG) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 16,675 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Celgene Corporation accounts for 0.1% of Moody National Bank Trust Division’s investment portfolio, making the stock its 28th biggest holding. Moody National Bank Trust Division’s holdings in Celgene Corporation were worth $2,166,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently bought and sold shares of CELG. Waldron LP raised its holdings in Celgene Corporation by 48.9% in the first quarter. Waldron LP now owns 5,207 shares of the biopharmaceutical company’s stock worth $640,000 after purchasing an additional 1,709 shares during the period. Acadian Asset Management LLC raised its holdings in Celgene Corporation by 98.0% in the first quarter. Acadian Asset Management LLC now owns 9,096 shares of the biopharmaceutical company’s stock worth $1,131,000 after purchasing an additional 4,501 shares during the period. Independent Portfolio Consultants Inc. raised its holdings in Celgene Corporation by 209.4% in the first quarter. Independent Portfolio Consultants Inc. now owns 1,541 shares of the biopharmaceutical company’s stock worth $192,000 after purchasing an additional 1,043 shares during the period. Meritage Portfolio Management acquired a new stake in Celgene Corporation in the first quarter worth $4,203,000. Finally, First Citizens Bank & Trust Co. raised its holdings in Celgene Corporation by 2.2% in the first quarter. First Citizens Bank & Trust Co. now owns 11,669 shares of the biopharmaceutical company’s stock worth $1,451,000 after purchasing an additional 255 shares during the period. Institutional investors own 79.33% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This report was reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.chaffeybreeze.com/2017/09/21/moody-national-bank-trust-division-has-2166000-position-in-celgene-corporation-celg.html.
Several equities research analysts have weighed in on CELG shares. Oppenheimer Holdings, Inc. set a $148.00 target price on shares of Celgene Corporation and gave the stock a “buy” rating in a report on Thursday, June 8th. Cann reiterated a “buy” rating on shares of Celgene Corporation in a report on Wednesday, June 7th. Canaccord Genuity set a $156.00 target price on shares of Celgene Corporation and gave the stock a “buy” rating in a report on Tuesday, June 6th. Mizuho increased their target price on shares of Celgene Corporation from $130.00 to $134.00 and gave the stock a “buy” rating in a report on Thursday, June 1st. Finally, BTIG Research reissued a “buy” rating and set a $138.00 price objective on shares of Celgene Corporation in a research report on Wednesday, May 24th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $149.34.
In related news, Director Gilla Kaplan sold 9,250 shares of the stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the completion of the transaction, the director now owns 85,551 shares in the company, valued at $12,110,599.56. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Ernest Mario sold 18,506 shares of the stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $130.52, for a total transaction of $2,415,403.12. Following the transaction, the director now owns 69,424 shares of the company’s stock, valued at approximately $9,061,220.48. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 63,006 shares of company stock valued at $8,490,806. 0.95% of the stock is owned by company insiders.
Shares of Celgene Corporation (NASDAQ:CELG) opened at 144.24 on Thursday. Celgene Corporation has a 1-year low of $96.93 and a 1-year high of $144.45. The stock’s 50 day moving average is $135.45 and its 200-day moving average is $127.81. The firm has a market cap of $112.85 billion, a PE ratio of 44.67 and a beta of 1.89.
Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.61 by $0.21. The company had revenue of $3.27 billion during the quarter, compared to analyst estimates of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The firm’s revenue for the quarter was up 18.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.44 earnings per share. Analysts expect that Celgene Corporation will post $7.32 earnings per share for the current year.
Celgene Corporation Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.